{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:28:39Z","timestamp":1791379719973,"version":"4.3.3"},"reference-count":87,"publisher":"MedWorks Media","issue":"4S1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacol Bull"],"abstract":"<jats:p>Purpose of Review\nThis is a review of elagolix use for pain related to endometriosis. It summarizes the background and recent data available about the pathogenesis of endometriosis and pain that is secondary to this syndrome. It then reviews the evidence to support the use of elagolix and the indications for use.\nRecent Findings\nEndometriosis occurs in 10% of reproductive-age women and is a common source of chronic pelvic pain, infertility, and co-morbid disorders. It usually presents with some combination of dysmenorrhea, dyspareunia, chronic pelvic pain, and infertility. Treatment options may be surgical or hormonal. Traditional treatment is divided into medical and surgical. The latter, though effective, is reserved for surgical emergencies and patients failing medical management. Medical management with NSAIDs is usually limited in efficacy. It is generally based on hormonal suppression leading to atrophy of endometrial lesions. Elagolix (Orlissa) is a GnRH antagonist that suppressed the entire hypophysis-gonadal axis. Reduced levels of estrogen and progesterone lead to involution of the endometrial lesions and improvement in symptoms. Clinical trials showed that elagolix is effective in treating dysmenorrhea and non-menstrual pain that is secondary to endometriosis. It is well tolerated and has a relatively safe usage profile. Studies up to 12 months long showed continued efficacy and reduction in dysmenorrhea of up to 75%, with 50%\u201360% reduction in non-menstrual pain. Elagolix was found effective when compared to both placebo and alternative treatments.\nSummary\nEndometriosis is a common syndrome that causes significant pain, morbidity, and disability, as well as financial loss. Elagolix is an effective drug in treating the symptoms of endometriosis and is a relatively safe option. Phase 4 studies will be required to evaluate the safety and efficacy of long term chronic use.<\/jats:p>","DOI":"10.64719\/pb.4390","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:39:16Z","timestamp":1761046756000},"page":"197-215","source":"Crossref","is-referenced-by-count":1,"title":["An Evidence-Based Review of Elagolix for the Treatment of Pain Secondary to Endometriosis"],"prefix":"10.64719","volume":"50","author":[{"given":"Ivan","family":"Urits","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leena","family":"Adamian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo","family":"Miro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Callan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parth M.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megha","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amnon A.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisham","family":"Kassem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Viswanath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54175","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"McLeod BS, Retzloff MG. Epidemiology of endometriosis: An assessment of risk factors. Clinical Obstetrics and Gynecology. 2010;53:389\u2013396. Lippincott Williams and Wilkins.","DOI":"10.1097\/GRF.0b013e3181db7bde"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Velebil P, Wingo PA, Xia Z, Wilcox LS, Peterson HB. Rate of hospitalization for gynecologic disorders among reproductive-age women in the United States. Obstet Gynecol. 1995;86(5):764\u2013769.","DOI":"10.1016\/0029-7844(95)00252-M"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Marinho MCP, Magalhaes TF, Fernandes LFC, Augusto KL, Brilhante AVM, Bezerra LRPS. Quality of Life in Women with Endometriosis: An Integrative Review. Journal of Women\u2019s Health. 2018;27:399\u2013408. Mary Ann Liebert Inc.","DOI":"10.1089\/jwh.2017.6397"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Johnson NP, Hummelshoj L, Adamson GD, Keckstein J, Taylor HS, Abrao MS, Bush D, Kiesel L, Tamimi R, Sharpe-Timms KL, Rombauts L, Giudice LC. World endometriosis society consensus on the classification of endometriosis. Hum Reprod. 2017;32(2):315\u2013324.","DOI":"10.1093\/humrep\/dew293"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"DiVasta AD, Vitonis AF, Laufer MR, Missmer SA. Spectrum of symptoms in women diagnosed with endometriosis during adolescence vs adulthood. Am J Obstet Gynecol. 2018;218(3):324.e1\u2013324.e11.","DOI":"10.1016\/j.ajog.2017.12.007"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Lagan\u00e0 AS, La Rosa VL, Rapisarda AMC, Valenti G, Sapia F, Chiofalo B, Rossetti D, Ban Frange\u017e H, Vrta\u010dnik Bokal E, Giovanni Vitale S. Anxiety and depression in patients with endometriosis: Impact and management challenges. Int J Womens Health. 2017;9:323\u2013330.","DOI":"10.2147\/IJWH.S119729"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Vitale SG, La Rosa VL, Rapisarda AMC, Lagan\u00e0 AS. Impact of endometriosis on quality of life and psychological well-being. Journal of Psychosomatic Obstetrics and Gynecology. 2017;38:317\u20139. Taylor and Francis Ltd.","DOI":"10.1080\/0167482X.2016.1244185"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Ameratunga D, Flemming T, Angstetra D, Ng SK, Sneddon A. Exploring the impact of endometriosis on partners. J Obstet Gynaecol Res. 2017;43(6):1048\u20131053.","DOI":"10.1111\/jog.13325"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Soliman AM, Yang H, Du EX, Kelley C, Winkel C. The direct and indirect costs associated with endometriosis: A systematic literature review. Human Reproduction. 2016;31:712\u2013722. Oxford University Press.","DOI":"10.1093\/humrep\/dev335"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Ferrero S, Evangelisti G, Barra F. Current and emerging treatment options for endometriosis. Expert Opinion on Pharmacotherapy. 2018;19:1109\u20131125. Taylor and Francis Ltd.","DOI":"10.1080\/14656566.2018.1494154"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Rogers PAW, D\u2019Hooghe TM, Fazleabas A, Gargett CE, Giudice LC, Montgomery GW, Rombauts L, Salamonsen LA, Zondervan KT. Priorities for endometriosis research: Recommendations from an international consensus workshop. Reprod Sci. 2009;16(4):335\u2013346.","DOI":"10.1177\/1933719108330568"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Cramer DW, Wilson E, Stillman RJ, Berger MJ, Belisle S, Schiff I, Albrecht B, Gibson M, Stadel BV, Schoenbaum SC. The Relation of Endometriosis to Menstrual Characteristics, Smoking, and Exercise. JAMA J Am Med Assoc. 1986;255(14):1904\u20131908.","DOI":"10.1001\/jama.1986.03370140102032"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Darrow SL, Vena JE, Batt RE, Zielezny MA, Michalek AM, Selman S. Menstrual cycle characteristics and the risk of endometriosis. Epidemiology. 1993;4(2):135\u2013142.","DOI":"10.1097\/00001648-199303000-00009"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Matalliotakis IM, Cakmak H, Fragouli YG, Goumenou AG, Mahutte NG, Arici A. Epidemiological characteristics in women with and without endometriosis in the Yale series. Arch Gynecol Obstet. 2008;277(5):389\u2013393.","DOI":"10.1007\/s00404-007-0479-1"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Duignan NM, Jordan JA, Coughlan BM, Logan-Edwards R. One thousand consecutive cases of diagnostic laparoscopy. J Obstet Gynaecol Br Commonw. 1972;79(11):1016\u20131024.","DOI":"10.1111\/j.1471-0528.1972.tb11880.x"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Williams TJ, Pratt JH. Endometriosis in 1,000 consecutive celiotomies: Incidence and management. Am J Obstet Gynecol. 1977;129(3):245\u2013250.","DOI":"10.1016\/0002-9378(77)90773-6"},{"key":"ref17","unstructured":"Hasson HM. Incidence of endometriosis in diagnostic laparoscopy. J Reprod Med Obstet Gynecol. 1976;16(3):135\u2013138."},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Matorras R, Rod\u00edquez F, Pijoan JI, Ram\u00f3n O, Gutierrez de Ter\u00e1n G, Rodr\u00edguez-Escudero F. Epidemiology of endometriosis in infertile women. Fertil Steril. 1995;63(1):34\u201338.","DOI":"10.1016\/S0015-0282(16)57293-8"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Barbieri RL. Reproductive history and endometriosis among premenopausal women. Obstet Gynecol. 2004;104(5):965\u2013974.","DOI":"10.1097\/01.AOG.0000142714.54857.f8"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Vercellini P, Eskenazi B, Consonni D, Somigliana E, Parazzini F, Abbiati A, Fedele L. Oral contraceptives and risk of endometriosis: A systematic review and meta-analysis. 2011;17:159\u2013170. Human Reproduction Update.","DOI":"10.1093\/humupd\/dmq042"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Rahmioglu N, Montgomery GW, Zondervan KT. Genetics of endometriosis. 2015;11:577\u2013586. Women\u2019s Health. Future Medicine Ltd.","DOI":"10.2217\/whe.15.41"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Vigan\u00f2 P, Infantino M, Lattuada D, Lauletta R, Ponti E, Somigliana E, Vignali M, DiBlasio AM. Intercellular adhesion molecule-1 (ICAM-1) gene polymorphisms in endometriosis. 2003;9:47\u201352. Molecular Human Reproduction.","DOI":"10.1093\/molehr\/gag002"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Simpson JL, Bischoff FZ. Heritability and molecular genetic studies of endometriosis. In: Annals of the New York Academy of Sciences. 2002:239\u2013251. New York Academy of Sciences.","DOI":"10.1111\/j.1749-6632.2002.tb02785.x"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Stefansson H, Geirsson RT, Steinthorsdottir V, Jonsson H, Manolescu A, Kong A, Ingadottir G, Gulcher J, Stefansson K. Genetic factors contribute to the risk of developing endometriosis. Hum Reprod. 2002;17(3):555\u2013559.","DOI":"10.1093\/humrep\/17.3.555"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Signorello LB, Harlow BL, Cramer DW, Spiegelman D, Hill JA. Epidemiologic determinants of endometriosis: A hospital-based case-control study. Ann Epidemiol. 1997;7(4):267\u2013274.","DOI":"10.1016\/S1047-2797(97)00017-3"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Dorgan JF, Reichman ME, Judd JT, Brown C, Longcope C, Schatzkin A, Albanes D, Campbell WS, Franz C, Kahle L, Taylor PR. The relation of body size to plasma levels of estrogens and androgens in premenopausal women (Maryland, United States) Cancer Causes Control. 1995;6(1):3\u20138.","DOI":"10.1007\/BF00051674"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Grodstein F, Goldman MB, Cramer DW. Infertility in women and moderate alcohol use. Am J Public Health. 1994;84(9):1429\u20131432.","DOI":"10.2105\/AJPH.84.9.1429"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Berube S, Marcoux S, Maheux R. Characteristics related to the prevalence of minimal or mild endometriosis in infertile women. Canadian Collaborative Group on Endometriosis. Epidemiology. 1998;9(5):504\u2013510.","DOI":"10.1097\/00001648-199809000-00006"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Baron JA, Vecchia C La, Levi F. The antiestrogenic effect of cigarette smoking in women. Am J Obstet Gynecol. 1990;162(2):502\u2013514.","DOI":"10.1016\/0002-9378(90)90420-C"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Shafrir AL, Farland LV, Shah DK, Harris HR, Kvaskoff M, Zondervan K, Missmer SA. Risk for and consequences of endometriosis: A critical epidemiologic review. Best Practice and Research: Clinical Obstetrics and Gynaecology. 2018","DOI":"10.1016\/j.bpobgyn.2018.06.001"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Arumugam K, Lim JMH. Menstrual characteristics associated with endometriosis. BJOG An Int J Obstet Gynaecol. 1997","DOI":"10.1111\/j.1471-0528.1997.tb14357.x"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Sangi-Haghpeykar H, Poindexter AN. Epidemiology of endometriosis among parous women. Obstet Gynecol. 1995","DOI":"10.1016\/0029-7844(95)00074-2"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Bravi F, Parazzini F, Cipriani S, Chiaffarino F, Ricci E, Chiantera V, Vigan\u00f2 P, La Vecchia C. BMJ open tobacco smoking and risk of endometriosis: A systematic review and meta-analysis. BMJ Open. 2014","DOI":"10.1136\/bmjopen-2014-006325"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Vitonis AF, Hankinson SE, Hornstein MD, Missmer SA. Adult physical activity and endometriosis risk. Epidemiology. 2010","DOI":"10.1097\/EDE.0b013e3181c15d40"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Cramer DW, Missmer SA. The epidemiology of endometriosis. In: Annals of the New York Academy of Sciences. 2002","DOI":"10.1111\/j.1749-6632.2002.tb02761.x"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Falcone T, Flyckt-Rebecca R. Clinical management of endometriosis. Obstet Gynecol. 2018","DOI":"10.1097\/AOG.0000000000002469"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Taylor HS, Adamson GD, Diamond MP, Goldstein SR, Horne AW, Missmer SA, Snabes MC, Surrey E, Taylor RN. An evidence-based approach to assessing surgical versus clinical diagnosis of symptomatic endometriosis. International Journal of Gynecology and Obstetrics. 2018","DOI":"10.1002\/ijgo.12521"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Brosens I, Puttemans P, Campo R, Gordts S, Kinkel K. Diagnosis of endometriosis: Pelvic endoscopy and imaging techniques. Best Practice and Research. Clinical Obstetrics and Gynaecology. 2004","DOI":"10.1016\/j.bpobgyn.2004.03.002"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Exacoustos C, Manganaro L, Zupi E. Imaging for the evaluation of endometriosis and adenomyosis. Best Pract Res Clin Obstet Gynaecol. 2014","DOI":"10.1016\/j.bpobgyn.2014.04.010"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Bazot M, Dara\u00ef E. Diagnosis of deep endometriosis: clinical examination, ultrasonography, magnetic resonance imaging, and other techniques. Fertility and Sterility. 2017","DOI":"10.1016\/j.fertnstert.2017.10.026"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Guerriero S, Saba L, Pascual MA, Ajossa S, Rodriguez I, Mais V, Alcazar JL. Transvaginal ultrasound vs magnetic resonance imaging for diagnosing deep infiltrating endometriosis: systematic review and meta-analysis. Ultrasound in Obstetrics and Gynecology. 2018","DOI":"10.1002\/uog.18961"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Kavoussi SK, Lim CS, Skinner BD, Lebovic DI, As-Sanie S. New paradigms in the diagnosis and management of endometriosis. Current Opinion in Obstetrics and Gynecology. 2016","DOI":"10.1097\/GCO.0000000000000288"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Sampson JA. Peritoneal endometriosis due to the menstrual dissemination of endometrial tissue into the peritoneal cavity. Am J Obstet Gynecol. 1927;14(4):422\u2013469.","DOI":"10.1016\/S0002-9378(15)30003-X"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Bulun SE. Endometriosis. 2009;360:268\u2013279. New England Journal of Medicine. Massachussetts Medical Society.","DOI":"10.1056\/NEJMra0804690"},{"key":"ref45","unstructured":"D\u2019hooghe TM, Debrock S. Endometriosis, retrograde menstruation and peritoneal in\u00afammation in women and in baboons"},{"key":"ref46","unstructured":"Sampson JA. Metastatic or Embolic Endometriosis, due to the Menstrual Dissemination of Endometrial Tissue into the Venous Circulation. Am J Pathol. 1927;3(2):93\u2013110.43."},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Meyer R. Zur Frage der heterotopen Epithelwucherung, insbesondere des Peritonealepithels und in den Ovarien. Virchows Arch Pathol Anat Physiol Klin Med. 1924;250(3):595\u2013610.","DOI":"10.1007\/BF01891397"},{"key":"ref48","unstructured":"Ferguson BR, Bennington JL, Haber SL. Histochemistry of mucosubstances and histology of mixed m\u00fcllerian pelvic lymph node glandular inclusions: Evidence for histogenesis by m\u00fcllerian metaplasia of coelomic epithelium. Obstet Gynecol. 1969;33(5):617\u2013625."},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Cousins FL, Dorien FO, Gargett CE. Endometrial stem\/progenitor cells and their role in the pathogenesis of endometriosis. 2018;50:27\u201338. Best Practice and Research: Clinical Obstetrics and Gynaecology. Bailliere Tindall Ltd.","DOI":"10.1016\/j.bpobgyn.2018.01.011"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Sasson IE, Taylor HS. Stem cells and the pathogenesis of endometriosis. In: Annals of the New York Academy of Sciences. 2008:106\u2013115. Blackwell Publishing Inc.","DOI":"10.1196\/annals.1434.014"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Burney RO, Giudice LC. Pathogenesis and pathophysiology of endometriosis. 2012;98:511\u2013519. Fertility and Sterility.","DOI":"10.1016\/j.fertnstert.2012.06.029"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Liu YG, Tekmal RR, Binkley PA, Nair HB, Schenken RS, Kirma NB. Induction of endometrial epithelial cell invasion and c-fms expression by transforming growth factor beta. Mol Hum Reprod. 2009;15(10):665\u2013673.","DOI":"10.1093\/molehr\/gap043"},{"key":"ref53","unstructured":"Oosterlynck DJ, Meuleman C, Waer M, Koninckx PR. Transforming growth factor-\u03b2 activity is increased in peritoneal fluid from women with endometriosis. Obstet Gynecol. 1994;83(2):287\u2013292."},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Osteen KG, Bruner KL, Sharpe-Timms KL. Steroid and Growth Factor Regulation of Matrix Metalloproteinase Expression and Endometriosis. Semin Reprod Endocrinol. 1996;14(3):247\u2013255.","DOI":"10.1055\/s-2007-1016334"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Kyama CM, Overbergh L, Debrock S, Valckx D, Vander Perre S, Meuleman C, Mihalyi A, Mwenda JM, Mathieu C, D\u2019Hooghe TM. Increased peritoneal and endometrial gene expression of biologically relevant cytokines and growth factors during the menstrual phase in women with endometriosis. Fertil Steril. 2006;85(6):1667\u20131675.","DOI":"10.1016\/j.fertnstert.2005.11.060"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Asante A, Taylor RN. The Annual Review of Physiology is online at. Annu Rev Physiol. 2011;73:163\u2013182.","DOI":"10.1146\/annurev-physiol-012110-142158"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"McLaren J, Prentice A, Charnock-Jones DS, Smith SK. Vascular endothelial growth factor (VEGF) concentrations are elevated in peritoneal fluid of women with endometriosis. Hum Reprod. 1996;11(1):220\u2013223.","DOI":"10.1093\/oxfordjournals.humrep.a019023"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Lucidi RS, Witz CA, Chrisco M, Binkley PA, Shain SA, Schenken RS. A novel in vitro model of the early endometriotic lesion demonstrates that attachment of endometrial cells to mesothelial cells is dependent on the source of endometrial cells. Fertil Steril. 2005;84(1):16\u201321.","DOI":"10.1016\/j.fertnstert.2004.10.058"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Patel BG, Lenk EE, Lebovic DI, Shu Y, Yu J, Taylor RN. Pathogenesis of endometriosis: Interaction between Endocrine and inflammatory pathways. Clinical Obstetrics and Gynaecology. 2018;50:50\u201360. Best Practice and Research. Bailliere Tindall Ltd.","DOI":"10.1016\/j.bpobgyn.2018.01.006"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Lebovic DI, Mueller MD, Taylor RN. Immunobiology of endometriosis. Fertility and Sterility. 2001;75:1\u201310.","DOI":"10.1016\/S0015-0282(00)01630-7"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Reis FM, Petraglia F, Taylor RN. Endometriosis: Hormone regulation and clinical consequences of chemotaxis and apoptosis. Hum Reprod Update. 2013;19(4):406\u2013418.","DOI":"10.1093\/humupd\/dmt010"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Coxon L, Horne AW, Vincent K. Pathophysiology of endometriosis-associated pain: A review of pelvic and central nervous system mechanisms. 2018;51:53\u201367. Best Practice and Research: Clinical Obstetrics and Gynaecology. Bailliere Tindall Ltd.","DOI":"10.1016\/j.bpobgyn.2018.01.014"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"Singh SS, Suen MWH. Surgery for endometriosis: beyond medical therapies. Fertility and Sterility. 2017","DOI":"10.1016\/j.fertnstert.2017.01.001"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"Duffy JMN, Arambage K, Correa FJS, Olive D, Farquhar C, Garry R, Barlow DH, Jacobson TZ. Laparoscopic surgery for endometriosis. Cochrane Database of Systematic Reviews. 2014","DOI":"10.1002\/14651858.CD011031.pub2"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"Jacobson TZ, Duffy JMN, Barlow DH, Farquhar C, Koninckx PR, Olive D. Laparoscopic surgery for subfertility associated with endometriosis. Cochrane Database of Systematic Reviews. 2014","DOI":"10.1002\/14651858.CD001398.pub3"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Afors K, Murtada R, Centini G, Fernandes R, Meza C, Castellano J, Wattiez A. Employing laparoscopic surgery for endometriosis. Women\u2019s Health. 2014","DOI":"10.2217\/WHE.14.28"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"Brown J, Crawford TJ, Allen C, Hopewell S, Prentice A. Nonsteroidal anti-inflammatory drugs for pain in women with endometriosis. Cochrane Database of Systematic Reviews. 2017","DOI":"10.1002\/14651858.CD004753.pub4"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"Madsen AM, Stark LM, Has P, Emerson JB, Schulkin J, Matteson KA. Opioid knowledge and prescribing practices among obstetrician-gynecologists. Obstet Gynecol. 2018","DOI":"10.1097\/AOG.0000000000002407"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"Brown J, Pan A, Hart RJ. Gonadotrophin-releasing hormone analogues for pain associated with endometriosis. Cochrane Database Syst Rev. 2010","DOI":"10.1002\/14651858.CD008475"},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"Taylor HS, Giudice LC, Lessey BA, Abrao MS, Kotarski J, Archer DF, Diamond MP, Surrey E, Johnson NP, Watts NB, Gallagher JC, Simon JA, Carr B, Dmowski WP, Leyland N, Rowan JP, Duan WR, Chwalisz K. Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist. N Engl J Med. 2017","DOI":"10.1056\/NEJMoa1700089"},{"key":"ref71","unstructured":"AbbVie Inc. Orlissa to Manage Moderate to Severe Endometriosis Pain [Internet] 2019"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"Lamb YN. Elagolix: First Global Approval. Drugs. 2018;78(14):1501\u20131508.","DOI":"10.1007\/s40265-018-0977-4"},{"key":"ref73","doi-asserted-by":"crossref","unstructured":"Hussar DA, Kaminski JE. Baricitinib, Tildrakizumab-asmn, and Elagolix sodium. J Am Pharm Assoc. 2018;58(6):685\u2013688.","DOI":"10.1016\/j.japh.2018.10.005"},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"Tan O, Bukulmez O. Biochemistry, molecular biology and cell biology of gonadotropin-releasing hormone antagonists. Curr Opin Obstet Gynecol. 2011;23(4):238\u2013244.","DOI":"10.1097\/GCO.0b013e328348a3ce"},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"Shebley M, Polepally AR, Nader A, Ng J, Winzenborg I, Klein CE, Noertersheuser P, Gibbs MA, Mostafa NM. Clinical Pharmacology of Elagolix: An Oral Gonadotropin-Releasing Hormone Receptor Antagonist for Endometriosis. Clin Pharmacokinet. 2019","DOI":"10.1007\/s40262-019-00840-7"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"Ng J, Chwalisz K, Carter DC, Klein CE. Dose-dependent suppression of gonadotropins and ovarian hormones by elagolix in healthy premenopausal women. J Clin Endocrinol Metab. 2017;102(5):1683\u20131691.","DOI":"10.1210\/jc.2016-3845"},{"key":"ref77","doi-asserted-by":"crossref","unstructured":"Ezzati M, Carr BR. Elagolix, a novel, orally bioavailable GnRH antagonist under investigation for the treatment of endometriosis-related pain. Women\u2019s Heal. 2015;11(1):19\u201328.","DOI":"10.2217\/WHE.14.68"},{"key":"ref78","doi-asserted-by":"crossref","unstructured":"Ng J, Duan WR, Marbury T, Schmidt JM, Klein CE. Elagolix Pharmacokinetic Profiles in Women With Renal or Hepatic Impairment. Clin Pharmacol Drug Dev. 2019;8(8):1053\u20131061.","DOI":"10.1002\/cpdd.640"},{"key":"ref79","doi-asserted-by":"crossref","unstructured":"Winzenborg I, Nader A, Polepally AR, Liu M, Degner J, Klein CE, Mostafa NM, Noertersheuser P, Ng J. Population Pharmacokinetics of Elagolix in Healthy Women and Women with Endometriosis. Clin Pharmacokinet. 2018;57(10):1295\u2013306.","DOI":"10.1007\/s40262-018-0629-6"},{"key":"ref80","doi-asserted-by":"crossref","unstructured":"Struthers RS, Nicholls AJ, Grundy J, Chen T, Jimenez R, Yen SSC, Bozigian HP. Suppression of gonadotropins and estradiol in premenopausal women by oral administration of the nonpeptide gonadotropin-releasing hormone antagonist elagolix. J Clin Endocrinol Metab. 2009;94(2):545\u2013551.","DOI":"10.1210\/jc.2008-1695"},{"key":"ref81","doi-asserted-by":"crossref","unstructured":"Diamond MP, Carr B, Dmowski WP, Koltun W, O\u2019Brien C, Jiang P, Burke J, Jimenez R, Garner E, Chwalisz K. Elagolix treatment for endometriosis-associated pain: Results from a phase 2, randomized, double-blind, placebo-controlled study. Reprod Sci. 2014;21(3):363\u2013371.","DOI":"10.1177\/1933719113497292"},{"key":"ref82","doi-asserted-by":"crossref","unstructured":"Surrey ES, Soliman AM, Agarwal SK, Snabes MC, Diamond MP. Impact of elagolix treatment on fatigue experienced by women with moderate to severe pain associated with endometriosis. Fertil Steril. 2019;112(2):298\u2013304.e3.","DOI":"10.1016\/j.fertnstert.2019.02.031"},{"key":"ref83","doi-asserted-by":"crossref","unstructured":"Surrey E, Taylor HS, Giudice L, Lessey BA, Abrao MS, Archer DF, Diamond MP, Johnson NP, Watts NB, Chris Gallagher J, Simon JA, Carr BR, Paul Dmowski W, Leyland N, Singh SS, Rechberger T, Agarwal SK, Chwalisz K. Long-term outcomes of elagolix in women with endometriosis results from two extension studies. Obstet Gynecol. 2018;132(1):147\u2013160.","DOI":"10.1097\/AOG.0000000000002675"},{"key":"ref84","doi-asserted-by":"crossref","unstructured":"Fourquet J, B\u00e1ez L, Figueroa M, Iriarte RI, Flores I. Quantification of the impact of endometriosis symptoms on health-related quality of life and work productivity. Fertil Steril. 2011;96(1):107\u2013112.","DOI":"10.1016\/j.fertnstert.2011.04.095"},{"key":"ref85","doi-asserted-by":"crossref","unstructured":"Pokrzywinski RM, Soliman AM, Chen J, Snabes M, Diamond MP, Surrey E, Coyne KS. Impact of elagolix on work loss due to endometriosis-associated pain: estimates based on the results of two phase III clinical trials. Fertil Steril. 2019;112(3):545\u2013551.","DOI":"10.1016\/j.fertnstert.2019.04.031"},{"key":"ref86","doi-asserted-by":"crossref","unstructured":"Carr B, Giudice L, Dmowski WP, O\u2019Brien C, Jiang P, Burke J, Jimenez R, Hass S, Fuldeore M, Chwalisz K. Elagolix, an oral GnRH antagonist for endometriosisassociated pain: A randomized controlled study. J Endometr Pelvic Pain Disord. 2013;5(3):105\u2013115.","DOI":"10.5301\/je.5000157"},{"key":"ref87","doi-asserted-by":"crossref","unstructured":"Carr B, Dmowski WP, O\u2019Brien C, Jiang P, Burke J, Jimenez R, Garner E, Chwalisz K. Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: Effects on bone mineral density. Reprod Sci. 2014;21(11):1341\u20131351.","DOI":"10.1177\/1933719114549848"}],"container-title":["Psychopharmacology Bulletin"],"original-title":[],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:28:24Z","timestamp":1791314904000},"score":1,"resource":{"primary":{"URL":"https:\/\/medworksmedia.com\/pb-article\/an-evidence-based-review-of-elagolix-for-the-treatment-of-pain-secondary-to-endometriosis\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":87,"journal-issue":{"issue":"4S1","published-online":{"date-parts":[[2025,8,12]]}},"URL":"https:\/\/doi.org\/10.64719\/pb.4390","relation":{},"ISSN":["2472-2448"],"issn-type":[{"value":"2472-2448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]}}}